Quick Answer
Inmune Bio, Inc. reported Research And Development Expense of $20.66 million for the year ending 2025.
- Inmune Bio, Inc. showed a decrease of -37.7% in Research And Development Expense from 2024 to 2025.
- This data is from Inmune Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Inmune Bio, Inc.'s Research And Development Expense has grown by 4,645.2%.
- Historical annual values: Fiscal year 2025: $20.66 million | Fiscal year 2024: $33.17 million | Fiscal year 2023: $20.27 million | Fiscal year 2022: $17.07 million | Fiscal year 2021: $20.54 million | Fiscal year 2020: $5.92 million | Fiscal year 2019: $3.28 million | Fiscal year 2018: $3.35 million | Fiscal year 2017: $435.4 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: